LyondellBasell heads into the final week of May with analysts trimming targets and options traders more defensive than at any point this year.
The most notable move came on May 27, when Citigroup's Patrick Cunningham cut his price target to $80 from $90, while holding a Buy rating. That reversal matters: Citi had raised the same target to $90 back in April. The round-trip signals that near-term commodity margin assumptions have deteriorated meaningfully in just six weeks. The broader analyst picture is mixed but directionally cautious. After a burst of upgrades in late April and early May — Morgan Stanley raised its target to $77 and RBC lifted to $94 — a second wave of cuts has since followed, with Wells Fargo trimming to $80 from $87. The Street's consensus still implies material upside: the mean target of $79.35 sits roughly 15% above the current price of $69.01. But the direction of travel has flipped from upward revision to downward pressure.
Options positioning reinforces the cautious tone. The put/call ratio has climbed to 1.22, almost at its 52-week high of 1.22 and running well above its 20-day average of 1.15, with a z-score of 1.4. That points to above-average demand for downside protection at a time when the stock has already shed 5.5% on the week and 1.2% over the past month. The borrow market, by contrast, tells a much more relaxed story: availability is extraordinarily loose at over 8,360% — meaning there is vastly more capacity to short the stock than there are shares already borrowed. Cost to borrow has ticked up 8% on the week to just 0.41%, but remains near its lowest levels of the year. Short interest is modest at 3.4% of the free float, up only fractionally on the week, and the ORTEX short score of 33.9 is low enough to suggest no meaningful bearish conviction from the lending market.
The factor picture has some genuine bright spots. EPS momentum scores rank in the 95th percentile on a 30-day basis and the 98th percentile over 90 days — a signal that analyst earnings revisions have been running hard to the upside ahead of Q2 results. The EPS surprise score also ranks in the 83rd percentile. That sits in sharp contrast to the valuation, where the EV/EBITDA multiple of 6.3x has fallen nearly 1.4 turns over the past 30 days, and the P/E of 7.8x has compressed by 3.4 points in the same window. The stock is getting cheaper on an earnings basis, but that re-rating is happening as the price falls rather than as earnings rise.
The insider activity from May 22 is worth noting in context rather than in isolation. Ten board members and directors sold small parcels on the same day, all at $69.72 — a pattern consistent with a scheduled compensation or equity-plan vest rather than any discretionary bearish conviction. Trade significance scores were all rated at 1 (low), and the largest individual sale was just under $99,000. Over the last 90 days, net insider activity has actually been a net positive at roughly $28 million of net share accumulation, suggesting no broad-based exit.
On the price side, LYB's 5.5% weekly decline broadly tracks its closest peer DOW, which fell 8.5% on the week — suggesting sector-wide pressure rather than a company-specific dislocation. CF Industries dropped 4.8% and Celanese fell 6.1% over the same stretch, making the chemicals complex broadly the weakest area of the industrial landscape this week. Q1 results on May 1 produced a 1.9% one-day gain but faded to a 3.8% loss over the following five sessions — a pattern the Street will watch for again when Q2 numbers land on July 31.
The next real catalyst is the July 31 earnings report. Between now and then, the key question is whether the upward EPS revision cycle that has driven the factor scores higher holds its momentum — or whether the Citi target cut is the first sign that commodity margin forecasts are rolling over again.
See the live data behind this article on ORTEX.
Open LYB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
